PT-141 (Bremelanotide) Dosage Guide

Complete guide to PT-141 (Bremelanotide) dosing protocols, administration methods, and safety considerations for research purposes.

Research Use Only: The dosage information provided is for educational and research purposes. Peptides are not approved by the FDA for human use. Always consult with a healthcare professional.

Recommended Dosage

FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month.

Administration Method

Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols.

Side Effects to Monitor

Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur.

Safety Considerations & Risks

Not recommended for use with alcohol. May cause significant nausea. Should not be used in patients with uncontrolled hypertension or cardiovascular disease.